PTC Therapeutics (PTCT)
(Delayed Data from NSDQ)
$51.11 USD
-1.14 (-2.18%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $51.11 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth F Momentum A VGM
Fundamental Charts
About Dividend Yield (TTM)
PTC Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
PTCT 51.11 -1.14(-2.18%)
Will PTCT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PTCT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PTCT
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
PTC Therapeutics (PTCT) Surges 11.2%: Is This an Indication of Further Gains?
PTCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Strength Seen in MiMedx (MDXG): Can Its 8.0% Jump Turn into More Strength?
All You Need to Know About PTC Therapeutics (PTCT) Rating Upgrade to Buy
Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy?
Other News for PTCT
SA analyst upgrades/downgrades: AMD, TSLA, SHEL, PTCT
Franklin Biotechnology Discovery Fund Q2 2025 Commentary
PTC Therapeutics: Uncertainty Abounds Ahead Of Q2 Earnings - I'm Upgrading To 'Hold'
PTCT Price Target Raised to $86 by Truist Securities | PTCT Stock News
PTC Therapeutics (PTCT) Sees Raised Price Target by B of A Securities | PTCT Stock News